This week’s Take 5 selection explores how organoid and microphysiological systems are moving from improved models to functionally predictive and therapeutically relevant platforms, spanning kidney disease, intestinal homeostasis, biomaterials engineering, and regenerative medicine.

A key theme is better prediction of drug response and disease progression.  Human-relevant 3D systems outperform traditional in vitro models by more accurately capturing key pathological processes such as inflammation, fibrosis, toxicity, and mechanistic drug responses, reflecting a broader move toward mechanism-first drug development, where organoids serve as decision-making tools rather than passive assay systems.

In parallel, tissue biology is being deciphered at increasing resolution.  Intestinal organoid models reveal how stem cell signalling balances proliferation and differentiation to maintain epithelial homeostasis, offering new insights into how disruption of these networks may contribute to gastrointestinal disease.  Similarly, biomaterials-driven advances show how scaffold design can actively shape tissue architecture and maturation, improving the fidelity and scalability of engineered organoid systems.

Technological innovation is another defining thread, with bioengineering and stem cell systems increasingly co-designed.  Progress in scaffold engineering and 3D culture control is enabling more reproducible and physiologically relevant tissue constructs, while multi-modal readouts link structure to function within a controlled microenvironment.

Most importantly, translation is becoming tangible and multi-directional.  A standout example is the derivation of PROCR+ pancreatic progenitor cells that generate functional islet organoids capable of restoring glycaemic control in vivo, including in preclinical large-animal models.  This moves organoids beyond disease modelling into the realm of cell-based regenerative therapies with direct clinical potential.

Overall, the trajectory is clear.  Organoid and microphysiological systems are evolving into integrated platforms that connect mechanism, prediction, and therapy, bridging fundamental biology and clinical application with increasing precision.

Source Articles:

Zuo, S. et al. (2026) Gut microbiota-M cell co-culture in inflammatory bowel disease and its therapeutic potential in organoid platforms. Front. Pharmacol. Sec. Gastrointestinal and Hepatic Pharmacology, 17; https://doi.org/10.3389/fphar.2026.1778142

de Cos, M. et al. (2026) Modelling Podocytopathies with Kidney Organoids. Nephrology Dialysis Transplantation; https://doi.org/10.1093/ndt/gfag091

Cottingham, K. (2026) Scientists uncover how the intestine balances cell growth and maintenance. Cornell Chronicle; https://news.cornell.edu/stories/2026/04/scientists-uncover-how-intestine-balances-cell-growth-and-maintenance

Jia, B. et al. (2026) Caspase 5c amplifies Wnt via APC cleavage to promote intestinal homeostasis. Nature; https://doi.org/10.1038/s41586-026-10343-8

Jabri, A. et al. (2026) Bioengineering Pancreatic Organoids and iPSC-Derived β-Cells for Diabetes: Materials, Devices, and Translational Challenges. Bioengineering, 13; https://www.mdpi.com/2306-5354/13/4/478

Song, W. et al. (2026) Generation and long-term expansion of human pancreatic islet organoids in vitro. bioRxiv; https://doi.org/10.64898/2026.04.15.718643